Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo

K. Schuster, J. Zheng, A. A. Arbini, Chengcheng Zhang, Pier P Scaglioni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The BCR/ABL tyrosine kinase promotes leukemogenesis through activation of several targets that include the phosphoinositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs), which target BCR/ABL, induce striking clinical responses. However, therapy with TKIs is associated with limitations such as drug intolerance, inability to universally eradicate the disease and emergence of BCR/ABL drug-resistant mutants. To overcome these limitations, we tested whether inhibition of the PI3K/target of rapamycin (mTOR) signaling pathway has antileukemic effect in primary hematopoietic stem cells and BA/F3 cells expressing the BCR/ABL oncoprotein. We determined that dual inhibition of PI3K/mTOR causes growth arrest and apoptosis leading to profound antileukemic effects both in vitro and in vivo. We also established that pharmacologic inhibition of the mTORC1/mTORC2 complexes is sufficient to cause these antileukemic effects. Our results support the development of inhibitors of the mTORC1/2 complexes for the therapy of leukemias that either express BCR/ABL or display deregulation of the PI3K/mTOR signaling pathway.

Original languageEnglish (US)
Article numbere34
JournalBlood Cancer Journal
Volume1
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

1-Phosphatidylinositol 4-Kinase
Protein Kinases
Protein-Tyrosine Kinases
Oncogene Proteins
Sirolimus
Hematopoietic Stem Cells
Pharmaceutical Preparations
Leukemia
Apoptosis
mechanistic target of rapamycin complex 1
In Vitro Techniques
Therapeutics
Growth

Keywords

  • CML
  • MTORC1/2
  • PI3K inhibitors
  • Targeted leukemia therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. / Schuster, K.; Zheng, J.; Arbini, A. A.; Zhang, Chengcheng; Scaglioni, Pier P.

In: Blood Cancer Journal, Vol. 1, No. 9, e34, 09.2011.

Research output: Contribution to journalArticle

@article{dfaf6aca298f4d2db5b8294fdd28285e,
title = "Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo",
abstract = "The BCR/ABL tyrosine kinase promotes leukemogenesis through activation of several targets that include the phosphoinositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs), which target BCR/ABL, induce striking clinical responses. However, therapy with TKIs is associated with limitations such as drug intolerance, inability to universally eradicate the disease and emergence of BCR/ABL drug-resistant mutants. To overcome these limitations, we tested whether inhibition of the PI3K/target of rapamycin (mTOR) signaling pathway has antileukemic effect in primary hematopoietic stem cells and BA/F3 cells expressing the BCR/ABL oncoprotein. We determined that dual inhibition of PI3K/mTOR causes growth arrest and apoptosis leading to profound antileukemic effects both in vitro and in vivo. We also established that pharmacologic inhibition of the mTORC1/mTORC2 complexes is sufficient to cause these antileukemic effects. Our results support the development of inhibitors of the mTORC1/2 complexes for the therapy of leukemias that either express BCR/ABL or display deregulation of the PI3K/mTOR signaling pathway.",
keywords = "CML, MTORC1/2, PI3K inhibitors, Targeted leukemia therapy",
author = "K. Schuster and J. Zheng and Arbini, {A. A.} and Chengcheng Zhang and Scaglioni, {Pier P}",
year = "2011",
month = "9",
doi = "10.1038/bcj.2011.30",
language = "English (US)",
volume = "1",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo

AU - Schuster, K.

AU - Zheng, J.

AU - Arbini, A. A.

AU - Zhang, Chengcheng

AU - Scaglioni, Pier P

PY - 2011/9

Y1 - 2011/9

N2 - The BCR/ABL tyrosine kinase promotes leukemogenesis through activation of several targets that include the phosphoinositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs), which target BCR/ABL, induce striking clinical responses. However, therapy with TKIs is associated with limitations such as drug intolerance, inability to universally eradicate the disease and emergence of BCR/ABL drug-resistant mutants. To overcome these limitations, we tested whether inhibition of the PI3K/target of rapamycin (mTOR) signaling pathway has antileukemic effect in primary hematopoietic stem cells and BA/F3 cells expressing the BCR/ABL oncoprotein. We determined that dual inhibition of PI3K/mTOR causes growth arrest and apoptosis leading to profound antileukemic effects both in vitro and in vivo. We also established that pharmacologic inhibition of the mTORC1/mTORC2 complexes is sufficient to cause these antileukemic effects. Our results support the development of inhibitors of the mTORC1/2 complexes for the therapy of leukemias that either express BCR/ABL or display deregulation of the PI3K/mTOR signaling pathway.

AB - The BCR/ABL tyrosine kinase promotes leukemogenesis through activation of several targets that include the phosphoinositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs), which target BCR/ABL, induce striking clinical responses. However, therapy with TKIs is associated with limitations such as drug intolerance, inability to universally eradicate the disease and emergence of BCR/ABL drug-resistant mutants. To overcome these limitations, we tested whether inhibition of the PI3K/target of rapamycin (mTOR) signaling pathway has antileukemic effect in primary hematopoietic stem cells and BA/F3 cells expressing the BCR/ABL oncoprotein. We determined that dual inhibition of PI3K/mTOR causes growth arrest and apoptosis leading to profound antileukemic effects both in vitro and in vivo. We also established that pharmacologic inhibition of the mTORC1/mTORC2 complexes is sufficient to cause these antileukemic effects. Our results support the development of inhibitors of the mTORC1/2 complexes for the therapy of leukemias that either express BCR/ABL or display deregulation of the PI3K/mTOR signaling pathway.

KW - CML

KW - MTORC1/2

KW - PI3K inhibitors

KW - Targeted leukemia therapy

UR - http://www.scopus.com/inward/record.url?scp=84864052108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864052108&partnerID=8YFLogxK

U2 - 10.1038/bcj.2011.30

DO - 10.1038/bcj.2011.30

M3 - Article

VL - 1

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 9

M1 - e34

ER -